Patents by Inventor Craig Jordan
Craig Jordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160058741Abstract: The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject.Type: ApplicationFiled: October 8, 2015Publication date: March 3, 2016Applicant: University of RochesterInventors: Craig Jordan, Monica Guzman
-
Patent number: 9180118Abstract: The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject.Type: GrantFiled: July 18, 2007Date of Patent: November 10, 2015Assignee: University of RochesterInventors: Craig Jordan, Monica Guzman
-
Publication number: 20150132315Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.Type: ApplicationFiled: September 5, 2014Publication date: May 14, 2015Applicant: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20140303389Abstract: A process for producing a food oil containing at least 50% monounsaturated fatty acids from palm oil is disclosed. Fatty acids are released from palm oil glycerides, such as by fat-splitting. The free fatty acids (FFA) are separated to obtain a fraction enriched in unsaturated palm fatty acid. This fraction is subject to a condensation reaction with glycerol to form an oil comprising mainly triglycerides (triacylglycerols). The condensation reaction is catalyzed by an enzyme.Type: ApplicationFiled: November 20, 2012Publication date: October 9, 2014Inventors: Thomas George Crosby, Marianne Linde Damstrup, John Inmok Lee, Per Munk Nielson, Craig Jordan Weitz
-
Patent number: 8852551Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: December 11, 2009Date of Patent: October 7, 2014Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20100133763Abstract: The working clearance height of a high-clearance vehicle is normally established by four main suspension spindles that are respectively received for reciprocating within upright journals provided at the opposite ends of front and rear axle assemblies of the vehicle main frame, with the bottom end each of the main spindles being received in a bore at the top of an associated wheel motor housing that serves also as a wheel hub mounting bracket. In order to increase the working clearance height of the vehicle, an optional elongate spacer assembly is mounted between the bottom of each elongate main suspension spindle and the associated wheel motor housing.Type: ApplicationFiled: December 3, 2008Publication date: June 3, 2010Inventors: Brandon Cy Carlson, Garry Eugene Baxter, Daniel Craig Jordan, Nathan D. Clarke, Scott Matthew Buse
-
Patent number: 7723019Abstract: A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.Type: GrantFiled: September 15, 2006Date of Patent: May 25, 2010Assignee: University of Kentucky Research FoundationInventors: Jeffrey Moscow, Xin Lu, Craig Jordan
-
Patent number: 7717443Abstract: The working clearance height of a high-clearance vehicle is normally established by four main suspension spindles that are respectively received for reciprocating within upright journals provided at the opposite ends of front and rear axle assemblies of the vehicle main frame, with the bottom end each of the main spindles being received in a bore at the top of an associated wheel motor housing that serves also as a wheel hub mounting bracket. In order to increase the working clearance height of the vehicle, an optional elongate spacer assembly is mounted between the bottom of each elongate main suspension spindle and the associated wheel motor housing.Type: GrantFiled: December 3, 2008Date of Patent: May 18, 2010Assignee: Deere & CompanyInventors: Brandon Cy Carlson, Garry Eugene Baxter, Daniel Craig Jordan, Nathan D. Clarke, Scott Matthew Buse
-
Publication number: 20100093003Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: ApplicationFiled: December 11, 2009Publication date: April 15, 2010Inventor: Craig Jordan
-
Publication number: 20100063109Abstract: The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject.Type: ApplicationFiled: July 18, 2007Publication date: March 11, 2010Applicant: University of RochesterInventors: Craig Jordan, Monica Guzman
-
Patent number: 7651678Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: April 23, 2004Date of Patent: January 26, 2010Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20080108513Abstract: The present invention relates to characterizing transcription within cells. In particular, the present invention provides transfected cell arrays (e.g., two-dimensional and/or three-dimensional arrays) and systems, kits and methods utilizing the same (e.g., for transcriptional activity characterization). Compositions and methods of the present invention find use in, among other things, research, drug discovery and clinical (e.g., diagnostic, preventative and therapeutic) applications.Type: ApplicationFiled: June 1, 2007Publication date: May 8, 2008Applicant: Northwestern UniversityInventors: Angela K. Pannier, Eric A. Ariazi, V. Craig Jordan, Lonnie D. Shea
-
Publication number: 20070269846Abstract: A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.Type: ApplicationFiled: September 15, 2006Publication date: November 22, 2007Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Jeffrey Moscow, Xin Lu, Craig Jordan
-
Publication number: 20070117132Abstract: An amplification-like, unidirectional dependence between expression levels in gene pairs is identified through statistical analysis including a determination of whether there is a specified level of independence (or non-correlation) between X and Z, where X is a random variable representing the expression level of a first gene, Y is a random variable representing the expression level of a second gene, and Y=XZ where Z?1. The disclosed process provides an ability to identify genes that act as “amplifiers,” thereby facilitating appropriate priority assignment to candidate genes for further evaluation and experimentation.Type: ApplicationFiled: November 7, 2006Publication date: May 24, 2007Inventors: Andrei Yakovlev, Lev Klebanov, Craig Jordan
-
Publication number: 20050272716Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, P6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 mType: ApplicationFiled: January 7, 2005Publication date: December 8, 2005Inventors: Peter Crooks, Craig Jordan, Xiaochen Wei
-
Publication number: 20050032886Abstract: Compounds of the formula having anti-tumor activity, wherein R1 and R2 are as described herein.Type: ApplicationFiled: July 9, 2004Publication date: February 10, 2005Inventors: Peter Crooks, Craig Jordan, Xiaochen Wei
-
Publication number: 20040197337Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R&agr; or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: ApplicationFiled: April 23, 2004Publication date: October 7, 2004Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventor: Craig Jordan
-
Patent number: 6753874Abstract: A method and apparatus for packing and unpacking pixels using a shift-down register and a shift-up register. In general, the shift-down register and shift-up register have the same bit storage capacity. In addition, the shift-down register and the shift-up register have a bit storage capacity larger in size than the bit storage capacity of the memory device from which the pixels are unpacked, or to which the pixels are packed.Type: GrantFiled: August 4, 2000Date of Patent: June 22, 2004Assignee: Microsoft CorporationInventors: Jeff S. Ford, Arthur McKinney, Craig Jordan
-
Patent number: 6733743Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R&agr; or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: March 6, 2001Date of Patent: May 11, 2004Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20030039611Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R&agr; or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: ApplicationFiled: March 6, 2001Publication date: February 27, 2003Inventor: Craig Jordan